|
gptkbp:instanceOf
|
gptkb:drug
antidote
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
V03AB38
|
|
gptkbp:CASNumber
|
1006822-07-2
|
|
gptkbp:contraindication
|
hypersensitivity to andexanet alfa
|
|
gptkbp:developedBy
|
gptkb:Portola_Pharmaceuticals
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Andexanet alfa
|
|
gptkbp:indication
|
apixaban reversal
rivaroxaban reversal
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
Andexxa
Ondexxya
|
|
gptkbp:mechanismOfAction
|
binds factor Xa inhibitors
restores factor Xa activity
|
|
gptkbp:molecularWeight
|
~39 kDa
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:PubChem_CID
|
DB13137
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
infusion-related reactions
thromboembolic events
|
|
gptkbp:synonym
|
coagulation factor Xa (recombinant), inactivated-zhzo
|
|
gptkbp:target
|
factor Xa inhibitors
|
|
gptkbp:UNII
|
Q2I0K1J1ZG
|
|
gptkbp:usedFor
|
life-threatening bleeding
reversal of anticoagulation
|
|
gptkbp:bfsParent
|
gptkb:Rivaroxaban
|
|
gptkbp:bfsLayer
|
7
|